Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Tumor progression is influenced by immune evasion mechanisms.
• Identifying pathways that downmodulate immune surveillance is crucial for developing antitumor therapies.

Purpose of the Study:

• To investigate the role of Signal transducer and activator of transcription 3 (Stat3) in immune cells within the tumor microenvironment.
• To determine if ablating Stat3 in hematopoietic cells can restore antitumor immunity.

Main Methods:

• Constitutive activation of Stat3 in tumor-infiltrating immune cells was assessed.
• Stat3 was genetically ablated in hematopoietic cells (Stat3(-/-)) of tumor-bearing mice.
• Immune cell function (dendritic cells, T cells, NK cells, neutrophils) and tumor growth/metastasis were evaluated.

Main Results:

• Constitutive Stat3 activation was observed in diverse tumor-infiltrating immune cells.
• Ablation of Stat3 in hematopoietic cells enhanced the function of multiple immune cell types, leading to inhibited tumor growth and metastasis.
• Targeting Stat3 with a small-molecule drug induced T cell- and NK cell-dependent tumor growth inhibition.

Conclusions:

• Stat3 signaling in hematopoietic cells acts as a key suppressor of natural tumor immune surveillance.
• Inhibiting Stat3 in tumor-bearing hosts can elicit a multicomponent therapeutic antitumor immune response.
• Targeting Stat3 represents a promising strategy for enhancing cancer immunotherapy.